
Beverages That Promote Hydration and Health Besides Water - Jordan News
Beverages That Promote Hydration and Health Besides Water Maintaining hydration is crucial for brain, gut, heart, and kidney health. It also helps regulate body temperature and prevents headaches. In addition to water, there are several other beverages that help hydrate the body while providing vitamins, minerals, antioxidants, and other nutrients. Here are some drinks that can enhance hydration and support overall health: اضافة اعلان Green Tea Green tea contains polyphenols, powerful antioxidants that help prevent cell damage and reduce inflammation. Drinking it has been shown to reduce the risk of diseases such as heart disease, cancer, Alzheimer's, and Parkinson's. Kombucha Kombucha is a fermented and sweetened tea that contains probiotics, which support gut health. It is also rich in polyphenols and may help lower cholesterol, prevent high blood pressure, improve liver function, and support gut health. Pomegranate Juice Pomegranate juice is rich in polyphenols and has heart health benefits. Studies show that drinking pomegranate juice daily can significantly lower blood pressure and reduce inflammation, as well as help manage diabetes. Kefir Kefir is a fermented milk drink that contains probiotics, which support gut health. It is an excellent source of calcium, vitamin D, and high-quality protein, which can benefit muscles and help you feel fuller longer. Sparkling Water Sparkling water is another option for staying hydrated. There are many flavored sparkling water options, but some may contain sweeteners that could raise blood sugar levels, so be mindful, especially for those with diabetes. Fruit Smoothies Fruit smoothies are a great way to consume more fruits and vegetables. They are rich in dietary fiber, which helps lower cholesterol, prevent constipation, reduce the risk of colon cancer, and aid in satiety. They also help prevent blood sugar spikes, making them more suitable for people with diabetes compared to fruit juice. Coffee Coffee contains beneficial plant nutrients, including chlorogenic acids, polyphenols, terpenoids, and alkaloids. Research shows that drinking coffee can help prevent inflammation, liver diseases, and neurological disorders. It may also help prevent colon and breast cancer. However, it's important not to exceed the safe caffeine intake, which is generally no more than four to five cups a day. Coconut Water Coconut water is often used as a natural sports drink. It contains potassium, sodium, magnesium, and calcium, which help support muscles and nerves, regulate heart rate, and maintain blood pressure. The potassium in coconut water may also help lower blood pressure. Some studies have found that drinking coconut water for a week can reduce blood pressure in adults with hypertension. Low-Fat Milk Milk is a good source of protein, making it an ideal post-workout drink to support muscle growth and rehydration. It also contains essential nutrients for bone health, including calcium, phosphorus, and vitamin D. Cranberry Juice Cranberry juice is a good source of vitamin C, an antioxidant that supports immune health. It is also rich in polyphenols that help prevent inflammation and may stop harmful bacteria from adhering to the walls of the bladder. Some research suggests that cranberry juice can help prevent urinary tract infections. Beetroot Juice Beetroot juice is rich in antioxidants, giving it its deep red color. It contains nitrates, which convert to nitric oxide after consumption. Nitrates help dilate blood vessels, improve blood flow, and lower blood pressure. Herbal Tea Herbal teas are caffeine-free and packed with nutrients. They contain antioxidants that help maintain cell health and prevent diseases like cancer, diabetes, and Alzheimer's. Each herbal tea has its unique flavor and health benefits. For example, ginger tea helps manage nausea, and hibiscus tea can help lower blood pressure.
Adding these beverages to your daily routine can help hydrate your body while promoting overall health naturally.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Michael J. Fox Will Return to Acting With Guest Role on ‘Shrinking' Season 3
Michael J. Fox will return to on-screen acting for the first time since his retirement in 2020 with a guest role on Season Three of the Apple TV+ show, Shrinking. As Variety reports, specific details about Fox's character and story arc on the critically acclaimed comedy are unknown at the moment. That said, it's possible Fox could be involved in a storyline tied to Harrison Ford's character, Paul, who was diagnosed with Parkinson's disease early in the show. Fox has been battling Parkinson's for over 30 years, and speech issues related to the disease were the reason he stepped away from acting in 2020. More from Rolling Stone Bono, Denzel Washington, Michael J. Fox to Receive Presidential Medal of Freedom Press Briefing Gets Heated Over Neurologist Visiting White House Coldplay's Record-Breaking Glastonbury Headlining Set Was Brilliant and Bizarre at Once Fox's Shrinking role will find him reuniting with Bill Lawrence, the series co-creator, who also helmed Spin City, the hit sitcom Fox starred in during the late Nineties. (He left the show in 2000 because of his early Parkinson's symptoms.) Fox later had a small guest role on another classic Lawrence sitcom, Scrubs, in 2004. Along with Fox, Shrinking Season Three is set to feature guest appearances from Jeff Daniels, Sherry Cola, and Isabella Gomez. The show's main cast boasts Ford, Jason Segel, Christa Miller, Jessica Williams, Luke Tennie, Michael Urie, Lukita Maxwell, and Ted McGinley. As for Fox, his last professional on-screen acting role was a two-episode spot on The Good Fight in 2020. The following year, he lent his voice to an animated short, Back Home Again, and appeared in the docuseries, Expedition: Back to the Future, about the search for the DeLorean Time Machine used in the classic film (the series featured Fox's co-star, Christopher Lloyd). In 2023, he appeared in Still: A Michael J. Fox Story, a documentary about his life, career, and Parkinson's battle. And though not technically acting, Fox did appear on a giant stage in June 2024 — Glastonbury, where he played guitar with Coldplay during their headlining set. Last year, Fox said he'd be open to returning to work in an interview with Entertainment Tonight. 'If someone offers me a part and I do it and I have a good time, great,' Fox said. 'I would do acting if something came up that I could put my realities into it, my challenges, if I could figure it out.' Best of Rolling Stone The 50 Best 'Saturday Night Live' Characters of All Time Denzel Washington's Movies Ranked, From Worst to Best 70 Greatest Comedies of the 21st Century
&w=3840&q=100)

Business Standard
3 hours ago
- Business Standard
Gujarat logs 108 new Covid-19 cases, Maharashtra confirms 86 infections
Gujarat and Maharashtra report a rise in Covid-19 cases linked to Omicron LF.7.9 and XFG sub-variants; officials advise caution but note symptoms remain mild Manikant Mishra New Delhi Gujarat has recorded 108 new Covid-19 cases and one death in the past 24 hours, according to a statement issued by the state health department on Tuesday. The latest spike has raised the number of active cases in the state to 461. Of these, 20 patients are receiving hospital care, while the remaining 441 are recovering in home isolation. The department also reported that 43 patients have been discharged after recovering. Health officials confirmed that the new infections are linked to the Omicron LF.7.9 and XFG Recombinant sub-variants. These variants are known to cause mild symptoms, primarily low-grade fever and cough. Authorities urged residents not to panic, stating that Covid-19 infections tend to follow a 'rising trend' every six to eight months. No additional information was provided regarding the deceased patient. Maharashtra registers 86 cases, four deaths Maharashtra reported 86 new Covid-19 infections on Tuesday, bringing the total number of cases recorded since 1 January 2025 to 959, according to the state health department. Of these, 435 individuals have recovered, while 510 cases remain active. The state has also reported four deaths since Monday—two in Nagpur, and one each in Chandrapur and Miraj. Among the new infections, Mumbai accounted for 26 cases, followed by Pune with 24, Thane city with 9, Navi Mumbai with 6, and Pimpri Chinchwad with 3. Kolhapur and Nagpur each reported 2 cases, while Kalyan, Ulhasnagar and Sangli reported 1 to 4 cases each. A few other regions also recorded isolated cases. Mumbai has reported 509 Covid-19 cases since January, with 503 of them recorded in May alone. Since the beginning of the year, Maharashtra has reported 14 Covid-related deaths. Of these, 13 patients had pre-existing medical conditions such as nephrotic syndrome with hypocalcaemic seizures, cancer, diabetic ketoacidosis, interstitial lung disease, cardiac arrhythmia and Parkinson's disease. One of the deceased was a 47-year-old woman who had presented symptoms of fever and shortness of breath. Since January 2025, Maharashtra has conducted 12,880 Covid-19 tests. Patients who test positive are receiving appropriate treatment, the department confirmed.
Yahoo
4 hours ago
- Yahoo
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for treatment-resistant depression (TRD), generally defined as a failure on two or more antidepressants. Alto paid Chase Therapeutics an upfront payment of $1.75 million. Chase Therapeutics will be eligible for up to $71.5 million in milestone payments, $41 million of the potential future milestone payments are tied to the product candidates' commercial success. Alto expects its current cash balance to support planned operations into 2028 through five clinical trial readouts across its pipeline most advanced program, ALTO-207 (formerly known as CTC-501), is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for Parkinson's disease with demonstrated antidepressant effect, and ondansetron, an antiemetic, selective 5-HT3 receptor antagonist. As a fixed-dose combination, ALTO-207 enables rapid titration and higher dosing by mitigating the dose-limiting adverse events typically experienced with pramipexole. Phase 2a trial of CTC-501 Chase Therapeutics completed a Phase 2a trial evaluating CTC-501 in 32 patients with depression. The primary endpoint was achieved in the study. Patients randomized to receive CTC-501 reached a mean dose of 4.1mg per day, with 67% achieving the highest allowable dose of 5mg/day. CTC-501 was generally well tolerated in the maintenance period of the study. CTC-501 demonstrated statistically significant and clinically meaningful improvements from baseline compared to placebo on depression symptoms as measured by the Montgomery Åsberg Depression Rating Scale or MADRS. CTC-501 also demonstrated significantly greater improvement on the Clinician Global Impression Scale of Severity (CGI-S) compared to placebo. Alto expects to initiate a Phase 2b trial, designed to be a potentially pivotal study, with ALTO-207 in patients with TRD by mid-2026 and report topline data in 2027. Phase 2a Trial For CTC-413 ALTO-208 (or CTC-413) is a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist. ALTO-208 is being developed for patients with Parkinson's disease (PD). Chase Therapeutics completed a blinded Phase 2a trial evaluating CTC-413 in 13 patients with PD. The mean tolerated dose of CTC-413 significantly exceeded pramipexole. Six subjects (67%) tolerated CTC-413 at the maximum dose of 9.0mg/day, and all but one remained on that dose throughout the final three-month treatment period. CTC-413 demonstrated favorable safety and tolerability with no unexpected, serious or persistent issues. William Blair reiterated an Outperform rating on Alto Neuroscience, viewing the acquisition of ALTO-207 as an 'intriguing asset.' The firm noted the impressive efficacy of pramipexole in the PAX-D study but also highlighted the possibility of functional unblinding in that study, which may have contributed to the perceived efficacy. Price Action: ANRO stock is trading higher by 2.31% to $2.66 at last check Tuesday Read Next:Photo by fizkes via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data